Orforglipron Beats Oral Semaglutide in Type 2 Diabetes Trial; Hair Loss on GLP-1s Addressed

In a head-to-head phase 3 trial, the daily oral weight loss pill orforglipron outperformed oral semaglutide on both blood sugar and weight in adults with type 2 diabetes. The ACHIEVE-3 trial, a 52-week randomized open-label study enrolling 1,698 adults across 131 medical centers in Argentina, China, Japan, Mexico and the United States, met its primary objective of non-inferiority and went further, achieving superiority on the primary endpoint and all key secondary endpoints.

Participants were assigned to one of four arms: orforglipron at 12 mg or 36 mg, or oral semaglutide at 7 mg or 14 mg. All participants started at a low dose and stepped up at four-week intervals to their assigned maintenance dose. One structural difference between the drugs matters for daily life. Orforglipron is a small molecule taken without food or water restrictions. Oral semaglutide is a peptide that must be taken on an empty stomach with a small sip of water, followed by a 30-minute wait before eating or drinking.

On blood sugar, participants taking 36 mg of orforglipron saw A1C fall by close to 2 percentage points, compared with roughly 1.5 points for those on 14 mg of oral semaglutide. On weight, the 36 mg orforglipron group lost 9.2 percent of body weight, roughly 19.7 pounds, against 5.3 percent, roughly 11.0 pounds, for oral semaglutide at 14 mg. The lower orforglipron dose of 12 mg produced 6.7 percent weight loss, about 13.7 pounds. The trial also reported improvements from baseline in cardiovascular risk factors including total cholesterol, triglycerides, and systolic blood pressure.

The result was not uniformly favorable. More participants stopped orforglipron because of adverse events. Discontinuation rates were 8.7 percent at the 12 mg dose and 9.7 percent at 36 mg, compared with 4.5 percent and 4.9 percent for oral semaglutide at 7 mg and 14 mg — roughly double. The most common adverse events were the same across both drugs: nausea, diarrhea, vomiting, dyspepsia and decreased appetite.

The trial was open-label, ran 52 weeks, and did not measure cardiovascular outcomes such as heart attack, stroke or cardiovascular death. The findings apply to adults with type 2 diabetes inadequately controlled on metformin and do not automatically extend to people without diabetes taking these drugs for weight or to people taking injectable GLP-1 medications. The study was funded by Eli Lilly, orforglipron's manufacturer.

Separately, dermatologists say hair shedding after starting GLP-1 medications such as Ozempic, Wegovy, or Mounjaro is frequently observed in clinical practice. They point out that the body often reacts to rapid weight loss as a stressor, potentially leading to a condition known as telogen effluvium. This is typically a temporary phase rather than permanent alopecia, and the hair growth cycle often stabilizes as the body adjusts to the new metabolic state, provided nutritional needs are met. Doctors recommend ensuring adequate protein and essential micronutrients, including iron, Vitamin D, and B12, to support follicle health during rapid weight loss. Once weight loss plateaus and the body stops being in a stress state, hair follicles shift back into the anagen (growth) phase.